TNF and irritable bowel syndrome: Data from the SECURE-IBD reported that compared with TNFα antagonist monotherapy, thiopurine monotherapy and combination therapy with TNFα antagonist and thiopurine were associated with an increased risk of severe COVID-19 [25].